Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Monte Rosa Therapeutics (GLUE) Accumulated Depreciation & Amortization (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Accumulated Depreciation & Amortization data on record, last reported at $21.3 million in Q1 2025.

  • For Q1 2025, Accumulated Depreciation & Amortization rose 50.66% year-over-year to $21.3 million; the TTM value through Mar 2025 reached $21.3 million, up 50.66%, while the annual FY2024 figure was $20.4 million, 66.32% up from the prior year.
  • Accumulated Depreciation & Amortization reached $21.3 million in Q1 2025 per GLUE's latest filing, up from $20.4 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $21.3 million in Q1 2025 and bottomed at $8.6 million in Q2 2023.
  • Average Accumulated Depreciation & Amortization over 3 years is $15.2 million, with a median of $15.2 million recorded in 2024.
  • Peak YoY movement for Accumulated Depreciation & Amortization: soared 89.16% in 2024, then skyrocketed 50.66% in 2025.
  • A 3-year view of Accumulated Depreciation & Amortization shows it stood at $12.2 million in 2023, then surged by 66.32% to $20.4 million in 2024, then grew by 4.62% to $21.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $21.3 million in Q1 2025, $20.4 million in Q4 2024, and $18.3 million in Q3 2024.